Navigation Links
Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences
Date:6/15/2010

acists, podiatrists, psychologists and other health care professionals.  More than 15,000 professionals gather each year to share research, treatment recommendations and advances toward a cure for diabetes.

About LX4211

LX4211 is an orally-delivered small molecule under development as a potential treatment for diabetes. LX4211 inhibits both sodium-glucose cotransporter type 2, or SGLT2, and sodium-glucose cotransporter type 1, or SGLT1.  SGLT2 is a transporter responsible for most of the glucose reabsorption performed by the kidney.  SGLT1 is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney.  In a combined Phase 1 single ascending-dose and multiple ascending-dose study, LX4211 was well tolerated at all dose levels and produced a dose-dependent increase in urinary glucose excretion. In preclinical studies, animals treated with LX4211 demonstrated increased urinary glucose excretion and decreased blood HbA1c levels (a marker of long-term blood sugar levels).  Importantly, urinary glucose excretion returned to baseline after treatment was discontinued.

For more information on LX4211, and to access the presentations (available after June 21 and 28, 2010, respectively), please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, i
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Decoding the dictionary: Study suggests lexicon evolved to fit in the brain
2. Heart of Herschel to be presented to media
3. Frontiers in Optics presents scientific advancements
4. Male contraception breakthroughs to be presented, Seattle Sept. 27-28
5. New book presents successful strategies for probing genetic variation
6. NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research
7. Chemical compound present in detergents produce bacteria alterations in agricultural soils
8. New book presents methods to poke and prod individual molecules
9. Present-day species of piranha result from a marine incursion into the Amazon Basin
10. Roger Kornberg to present lecture at the Joint Biophysical Society/IUPAB Meeting
11. Internationally recognized experts presents a complete overview on hydroecology and ecohydrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... in the West African nation Burkina Faso today ... Sayana Press has the potential to increase access ... system and in communities by combining a lower-dose ... medroxyprogesterone acetate)with the BD Uniject injection system. , ... countries expected to begin introducing Sayana Press in ...
(Date:7/9/2014)... healthy women differ from bacteria in women with ... from Loyola University Chicago Stritch School of Medicine. ... in the American Society for Microbiology,s online journal ... play a role in female urinary health. , ... poorly understood, condition with symptoms similar to urinary ...
(Date:7/9/2014)... Cancer Research Centre (CNIO) have discovered that NANOG, an ... division in stratified epitheliathose that form part of the ... the vaginain adult organisms. According to the conclusions of ... , this factor could also play a role in ... the oesophagus and skin. , The pluripotency factor NANOG ...
Breaking Biology News(10 mins):Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 2Injectable contraceptive launched in Burkina Faso to expand choice and address unmet need 3CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2
... the limits of life in extreme environments, scientists have discovered ... an Antarctic lake sealed under more than 65 feet of ... the Proceedings of the National Academy of Sciences , ... been isolated from the surface environment -- and external sources ...
... Johns Hopkins researchers report concrete steps in the use of ... drugs. Their success highlights a pathway toward faster, cheaper drug ... to pre-test a therapy,s safety and effectiveness on cultured clones ... in an article published November 25 on the website of ...
... the first time that marine algae can be just as ... scientists genetically engineered marine algae to produce five different kinds ... used could be employed to enhance the yield of petroleum-like ... in a paper published online in the current issue of ...
Cached Biology News:UIC scientists find ancient microbes in salty, ice-sealed Antarctic lake 2Study advances use of stem cells in personalized medicine 2Bioengineered marine algae expands environments where biofuels can be produced 2
(Date:1/15/2014)... device," Nobel laureate Herbert Kroemer famously observed, referring ... the junctures where layers of different materials meet. ... between layers of metal oxides are becoming increasingly ... spintronics, high-temperature superconductors, ferroelectrics and multiferroics. Realizing the ...
(Date:1/15/2014)... 15, 2014 Look inside the new ... for the lab, from fluid handling to instruments to ... ship when you order. , Preferred Solutions features ... from the L/S® model for precise flow control and ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... PAREXEL International Corporation (Nasdaq: PRXL ) will ... January 31, 2011 after the close of the stock market. ... www.PAREXEL.com and on the PR Newswire website at ... and live webcast at 10:00 a.m. EST on Tuesday, February ...
... 2011 Advanced Pain Remedies (APR), a subsidiary of ... has been received, to advance its lead development candidate, ... targeting of specific cell types to manipulate them for ... million grant from the National Cancer Institute (NCI). Advanced ...
... CITY, Kan., Jan. 7, 2011 Aratana Therapeutics, a newly-formed ... animal health industry, today announced that it has closed a ... Avalon Ventures. "At Aratana, we will be focused ... them in new ways to treat and care for animals," ...
Cached Biology Technology:PAREXEL Announces Date of Second Quarter Fiscal Year 2011 Earnings Release and Conference Call 2Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP 2Advanced Pain Remedies, a Subsidiary of Cato BioVentures, Announces a Three Million Dollar Award from the National Cancer Institute for SP-SAP 3